ConductScience.org, home

Paper131986

Inhibition of plasmin by normal and antiplasmin-depleted human plasma.

Edy J and 2 others. Thromb Res, 1976. Cited by 104 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Inhibition of plasmin by normal and antiplasmin-depleted human plasma. Papers, record 131986. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/131986

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Inhibition of plasmin by normal and antiplasmin-depleted human plasma.
PubMed
Journal
Thromb Res
PubMed
Year
1976
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
104
iCite
Relative citation ratio, by iCite
4.17
iCite
Revised in PubMed
2019-07-27
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Edy JJ
2De Cock FF
3Collen DD

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
FibrinolysinMajor topic
Immune SeraMajor topic
Humans
Immunoelectrophoresis
In Vitro Techniques
Protease Inhibitors
Time Factors

Source PubMed

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 104 citations.

PMIDTitleJournalYearIn PapersSource
7,199,539Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.J Clin Invest1982https://conductscience.org/library/papers/7199539PubMed
6,681,615
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
J Clin Invest1983https://conductscience.org/library/papers/6681615PubMed
6,479,679Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance.Gut1984https://conductscience.org/library/papers/6479679PubMed
3,118,374Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.Proc Natl Acad Sci U S A1987https://conductscience.org/library/papers/3118374PubMed
3,088,040Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components.J Clin Invest1986https://conductscience.org/library/papers/3088040PubMed
1,946,453A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.Proc Natl Acad Sci U S A1991https://conductscience.org/library/papers/1946453PubMed
399,646Mechanisms of deep vein thrombosis: a review.J R Soc Med1979https://conductscience.org/library/papers/399646PubMed
68,962The behavior of alpha2-plasmin inhibitor in fibrinolytic states.J Clin Invest1977https://conductscience.org/library/papers/68962PubMed

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
PLG5,340PubTator's text mininghttps://conductscience.org/library/genes/5340

Source NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/131986

GET https://conductscience.org/api/papers/v1/131986/authors